|
|
|
| Efficacy of TCD and BCD in Initial Treatment of Multiple Myeloma |
| WANG Ming-di, CUI Hai-jia, WU Dao-xiang,et al |
| Department of Hematology, Shougang Hospital, Peking University, Beijing 100041 |
|
|
|
|
Abstract 【Objective】To explore the survival rate and safety of TCD and BCD in the treatment of multiple myeloma(MM).【Method】Seventy-two patients with MM were enrolled in our hospital. The patients were divided into A group and B group by treatment methods, with 36 cases in each group. The A group was treated with the TCD regimen and the B group was treated with the BCD regimen. The clinical efficacy and serum levels of β2-microglobulin(β2-MG), C-reactive protein(CRP), and serum creatinine(Cr) were compared between the two groups. The tumor markers such as antigen(CEA), carbohydrate antigen 125(CA125), neuron-specific enolase(NSE) and cytokeratin fragment antigen 21-1(CYFRA21-1) were compared as well between the two groups before and after treatment. The survival rate and incidence of adverse reactions between the two groups were analyzed.【Results】The total effective rate of 63.89%(23/36) in the A group was significantly lower than that in the B group(88.89%, 32/36)(P<0.05). The difference of Cr in the A group was significantly lower than that in the B group(P<0.05). After treatment, the β2-MG and CRP levels in the two groups were significantly lower (P< 0.05). However, there was no significant difference between the two groups in either before or after treatment(P>0.05). Compared to before treatment, levels of CEA, CA125 and NSE were significantly lower in both groups after the treatment(P<0.05). While there was no significant difference between the two groups in either before or after treatment with CEA, CA125 and NSE(P>0.05). The survival rate was similar; And the difference was not statistically significant(P>0.05). The total incidence of adverse reactions in the A group was 25.00% compared with 19.44% in the B group, and the difference was not statistically significant(P>0.05).【Conclusion】The BCD regimen is used in the treatment of newly diagnosed MM. The safety and survival rate are comparable to those of the TCD regimen. It is better than the TCD regimen and worthy of clinical attention.
|
|
Received: 10 January 2021
|
|
|
|
|
|
[1] PAWLYN C, MORGAN G J. Evolutionary biology of high-risk multiple myeloma[J].Nature Reviews Cancer,2017, 17(9):543-556.
[2] 陈文萃,李婷. 多发性骨髓瘤的诊断和治疗进展[J].肾脏病与透析肾移植杂志, 2019, 28(1):78-82.
[3] 中国医师协会血液科医师分会, 中国多发性骨髓瘤工作组. 中国多发性骨髓瘤诊治指南(2013年修订)[J].中华内科杂志, 2013, 52(9):791-795.
[4] 傅郁华, 胡晓霞, 陈莉, 等. RISS新分期系统对多发性骨髓瘤预后意义的评估分析[J].肿瘤, 2018, 38(4):71-79.
[5] 陈楠. 重视多发性骨髓瘤肾损伤的诊断与治疗[J].中华内科杂志, 2017, 56(11):795-797.
[6] 刘扬, 温磊, 王国苗,等. BCD方案不同疗程数对于初治多发性骨髓瘤的疗效影响[J].中国肿瘤临床, 2018, 45(11):553-556.
[7] 李鑫. 以硼替佐米为基础的化疗方案治疗多发性骨髓瘤的疗效及其对血液指标的影响[J].中国实用乡村医生杂志, 2018, 25(6):62-64.
[8] 滑欢, 张学军. 多发性骨髓瘤患者肿瘤细胞免疫表型特点及临床意义分析[J].河北医科大学学报, 2018, 39(7):763-768.
[9] 于晓晨, 苏薇, 庄俊玲. 重轻链检测在多发性骨髓瘤疗效评价中的意义[J].中华血液学杂志, 2018, 39(4):281-285.
[10] 施玲玲, 翟勇平. 多发性骨髓瘤细胞对硼替佐米耐药机制的研究进展[J].中国实验血液学杂志, 2017, 25(5):1576-1579.
[11] 张丽, 罗文达, 沈健,等. 含硼替佐米的联合化疗对多发性骨髓瘤的治疗效果及不良反应[J].中华全科医学, 2016, 14(11):1826-1828. |
|
|
|
2021, Vol. 38 
